couter

ADMAADMA Biologics, Inc.

Health CareBiotechnology

ADMA Biologics, Inc. sells biologics and immunotherapies, with a focus on rare diseases and oncology. The next catalyst is Sep 28, 2026 — Why Adma Biologics (ADMA) Dipped More Than Broader Market Today, which will test the company’s ability to manage ongoing securities fraud allegations and stabilize its revenue trajectory.

  • ADMA reported $495.10M in revenue for the second quarter of 2026, with a net margin of 33.3% and free cash flow of $126.30M.
  • The company has a debt-to-equity ratio of 0.16x, and shareholders’ equity stands at $477.32M.
  • Revenue grew 19.6% year-over-year, but recent guidance cuts and legal exposure have pressured the stock.

The Read

4% following Q1 2026 results due to revenue decline, lowered outlook, and securities fraud probes over channel stuffing.
Sep 30, 2026 — Audit & Securities Fraud Investigation
Chart by TradingView

The schedule

  • Wed30Sep

    Audit & Securities Fraud Investigation

  • Wed4Nov

    JP Morgan Healthcare Conference

  • Tue12Jan

    Trump Administration Healthcare Policy Update

  • Mon25Jan

    Trump Administration Healthcare Policy Update

  • Tue9Feb
  • Wed5May
  • Wed4Aug

Past

  • Mon28Sep

    Actual outcome: Bull

    Price reached or exceeded bull target ($9.95) at outcome date.

    Why Adma Biologics (ADMA) Dipped More Than Broader Market Today

  • Wed5Aug

    Actual outcome: Bull · $9.75 at outcome

    ADMA reported in-line EPS but missed revenue due to BIVIGAM pressure, yet reiterated full-year guidance and highlighted stabilization in BIVIGAM utilization. The stock rallied on optimism around ASCENIV growth and sustained demand, overshadowing the revenue miss.

  • Wed6May

    Actual outcome: Bear · $8.50 at outcome

    ADMA reported in-line EPS of $0.19, but revenues slipped and management cut its 2026 outlook due to immune globulin market pressure. The lowered forward guidance, compounded by severe channel stuffing allegations that triggered multiple securities fraud investigations, drove a sharp sell-off in the stock.

  • Wed25Feb

    Actual outcome: Mixed · $15.70 at outcome

    ADMA reported Q4 2025 EPS of $0.21, exactly matching consensus estimates. With earnings meeting expectations and 2026 guidance offering no major surprises, the market reaction was muted, leaving the stock flat through the outcome date.